Skip to main content
logo
C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.060
-0.120 (-3.77%)
At close: Oct 23, 2026, 4:00 PM EDT
3.060
0.00 (0.00%)
Pre-market: Oct 26, 2026, 4:08 AM EDT

C4 Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
35.0435.9535.5820.7631.145.79
Revenue Growth
2.33%1.02%71.44%-33.25%-32.08%37.93%
Gross Profit
30.2526.9723.05-96.95-86.75-48.88
Operating Income
-101.03-104.49-117.18-139.03-129.53-82.13
Net Income
-101.42-104.99-105.32-132.49-128.18-83.89
Earnings Per Share
-0.91-1.27-1.52-2.67-2.62-1.82
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
300.45297.1267.26281.69337.12451.48
Total Debt
56.8659.9865.7670.9887.1542.88
Net Cash (Debt)
243.59237.12201.51210.71249.96408.6
Net Cash Growth
52.20%17.67%-4.37%-15.70%-38.82%17.16%
Net Cash Per Share
2.182.862.904.245.128.87

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-84.87-98.69-65.16-106.84-105.94-86.97
Capital Expenditures
-0.52-0.61-0.18-1.71-5.5-1.28
Free Cash Flow
-85.39-99.3-65.34-108.55-111.44-88.24
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
86.34%75.03%64.76%--278.96%-106.76%
Operating Margin
-288.34%-290.68%-329.30%-669.83%-416.56%-179.39%
Pretax Margin
-289.09%-291.74%-295.60%-632.17%-412.19%-183.23%
Profit Margin
-289.44%-292.08%-295.96%-638.34%-412.19%-183.23%
FCF Margin
-243.71%-276.24%-183.61%-522.96%-358.36%-192.73%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
10.745.157.1413.429.2934.20